Tempus AI: Another Post-Earnings Dip Worth Buying

Tempus AI presents a compelling long-term opportunity, with strong data adoption and an expanding addressable market beyond Oncology. Q1 showed mixed results: robust Oncology testing, Hereditary weakness, decelerating revenue growth, but narrowing losses and gross margin expansion. Record $1.1B TCV and 126% net revenue retention underscore Tempus AI's durable value proposition and client stickiness.